1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Bangladesh Pharmaceuticals and Healthcare Report Q1 2017

Bangladesh Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 84 pages

Includes 3 FREE quarterly updates


BMI View:

Bangladesh’s long-term potential will be the central factor shaping its attractiveness to multinational drugmakers. Rising household incomes - coupled with improving healthcare access, driven largely by the influx of private hospitals into the country - bode well for sustained strong growth from a low base. In the short term, growth opportunities lie largely in driving higher volumes and are concentrated in major cities such as Dhaka and Chittagong.

Headline Expenditure Projections



- Pharmaceuticals: BDT171.6bn (USD2.2bn) in 2015 to BDT190.8bn (USD2.4bn) in 2016; +11.2% in local currency terms and +8.8% in US dollar terms. Forecast revised downwards from last quarter.

- Healthcare: BDT419.1bn (USD5.4bn) in 2015 to BDT460.8bn (USD5.8bn) in 2016; +9.9% in local currency terms and +7.6% in US dollar terms. Forecast unchanged from last quarter. In Q117, Bangladesh’s Risk/Reward Index (RRI) score remains unchanged from last quarter at 41.8 out of 100. Bangladesh also retains its ranking position in BMI’s RRI matrix, standing as the 15th most attractive market to pharmaceutical investors out of 19 markets in the Asia Pacific region. Bangladesh’s score is driven by a large pharmaceutical market (market expenditure score of 10.0 out of 20) and rapid drug market expansion (sector value growth score of 8.4 out of 12), but is dragged down by low levels of drug spending per capita (spending per capita score of 1.2 out of 12) and limited intellectual property protection (patent respect score of 1.4 out of 7).

Table Of Contents

Bangladesh Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Bangladesh 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Bangladesh 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2012-2020) 16
Prescription Drug Market Forecast 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2012-2020) 18
Patented Drug Market Forecast 19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2012-2020) 20
Generic Drug Market Forecast 21
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2012-2020) 22
OTC Medicine Market Forecast 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Bangladesh 2012-2020) 24
Pharmaceutical Trade Forecast 25
Table: Pharmaceutical Trade Data And Forecasts (Bangladesh 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Bangladesh 2014-2020) 27
Pharmaceuticals and Healthcare Risk/Reward Index 28
Asia Pacific Risk/Reward Index 28
Bangladesh Risk/Reward Index 34
Rewards 34
Risks 35
Regulatory Review 36
Table: Steps To Establish A Pharmaceutical Manufacturing Unit And Obtain A Drug Manufacturing Licence 38
Intellectual Property Issues 38
Pricing and Reimbursement Regime 40
Market Overview 43
Healthcare Sector 43
Table: Healthcare Resources (Bangladesh 2010-2015) 47
Table: Healthcare Personnel (Bangladesh 2010-2015) 47
Table: Healthcare Activity (Bangladesh 2010-2015) 48
Research and Development 49
Table: Suggestions Made By University Of Dhaka's Faculty Of Pharmacy To Improve Pharmaceutical Research 50
Clinical Trials 51
Epidemiology 52
Competitive Landscape 54
Research-Based Industry 54
Table: Table: Multinational Market Activity 55
Pharmaceutical Distribution 56
Company Profile 57
Beximco Pharmaceuticals 57
Eskayef 61
Renata 64
Sanofi 67
Square Pharmaceuticals 70
Demographic Forecast 73
Table: Population Headline Indicators (Bangladesh 1990-2025) 74
Table: Key Population Ratios (Bangladesh 1990-2025) 74
Table: Urban/Rural Population and Life Expectancy (Bangladesh 1990-2025) 75
Table: Population By Age Group (Bangladesh 1990-2025) 75
Table: Population By Age Group % (Bangladesh 1990-2025) 76
Glossary 78
Methodology 80
Pharmaceutical Expenditure Forecast Model 80
Healthcare Expenditure Forecast Model 80
Notes On Methodology 81
Risk/Reward Index Methodology 82
Index Overview 83
Table: Pharmaceutical Risk/Reward Index Indicators 83
Indicator Weightings 84

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.